Logo

Matritech Launches New Website; Promotes Sales of FDA-Approved Bladder Cancer Products

Aug 13, 2004

NEW YORK, Aug. 13 (GenomeWeb News)- Matritech, a developer of protein-based diagnostics products for early detection of cancer, announced today that it has launched its new website at www.matritech.com

 

Designed by Boston-based Weymouth Design, Matritech's new website provides updated information on the company's products that are in development and on the market, and allows physicians to order Matritech's NMP22 BladderChek Test online.

 

Matritech's first two products, the NMP22 BladderChek test and NMP22 test kit have been approved by the US Food and Drug Administration for the monitoring and diagnosis of bladder cancer. Aside from developing products for bladder cancer, the company has also used its proteomics technology to discover proteins associated with cervical, prostate, breast and colon cancer.

 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.